stockrowNeogen Corporation
NEOG Healthcare Medical Devices
Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.
- Revenue
- +6.50%
- EPS
- −129.4%
- Free cash flow
- +135.6%
- Total debt
- −2.31%
Quarter to August 2026, against a year earlier
Follow NEOG
Alert me
Neogen Corporation (NEOG) Revenue
Neogen Corporation's revenue for fiscal 2026 was $870.4M, unchanged from fiscal 2025. Over the twelve months to 31 August 2026 it was $884.0M. Over the past ten years it has ranged from $283.1M (fiscal 2015) to $924.2M (fiscal 2024); the current reading is higher than 83% of that period. Neogen Corporation ranks 28th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2026 | $870.4M | (2.72%) |
| FY2025 | $894.7M | (3.19%) |
| FY2024 | $924.2M | 12.37% |
| FY2023 | $822.4M | 56.01% |
| FY2022 | $527.2M | 12.53% |
| FY2021 | $468.5M | 12.03% |
| FY2020 | $418.2M | 0.96% |
| FY2019 | $414.2M | 4.09% |
| FY2018 | $397.9M | 11.07% |
| FY2017 | $358.3M | 11.52% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Aug 2026 | $222.8M | (1.11%) |
| May 2026 | $225.3M | 6.68% |
| Feb 2026 | $211.2M | (6.00%) |
| Nov 2025 | $224.7M | 7.40% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ITGR Integer Holdings Corporation compare | $1.8B |
| NEOG Neogen Corporation | $884.0M |
| INSP Inspire Medical Systems, Inc. compare | $880.9M |
| TMDX TransMedics Group, Inc. compare | $727.7M |
| UFPT UFP Technologies, Inc. compare | $649.5M |
| AXGN AxoGen, Inc. compare | $266.9M |
| ESTA Establishment Labs Holdings Inc. compare | $245.8M |
| BFLY Butterfly Network, Inc. compare | $123.3M |
| ALMR Alamar Biosciences, Inc. compare | $105.2M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on NEOG
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement